Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential

Andrea Chiricozzi,1,2 Clara De Simone,1,2 Barbara Fossati,2 Ketty Peris1,21Institute of Dermatology, Catholic University, Rome, Italy; 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyAbstract: Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chiricozzi A, De Simone C, Fossati B, Peris K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	psoriasis psoriatic arthritis bimekizumab bispecific agent dualspecific agent Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/b3f9927d63c04c45a0347abf4a3d2e87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b3f9927d63c04c45a0347abf4a3d2e87
record_format	dspace
spelling	oai:doaj.org-article:b3f9927d63c04c45a0347abf4a3d2e872021-12-02T05:28:28ZEmerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential2230-326Xhttps://doaj.org/article/b3f9927d63c04c45a0347abf4a3d2e872019-05-01T00:00:00Zhttps://www.dovepress.com/emerging-treatment-options-for-the-treatment-of-moderate-to-severe-pla-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XAndrea Chiricozzi,1,2 Clara De Simone,1,2 Barbara Fossati,2 Ketty Peris1,21Institute of Dermatology, Catholic University, Rome, Italy; 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyAbstract: Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.Keywords: psoriasis, psoriatic arthritis, bimekizumab, bispecific agent, dual specific agentChiricozzi ADe Simone CFossati BPeris KDove Medical Pressarticlepsoriasispsoriatic arthritisbimekizumabbispecific agentdualspecific agentDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 9, Pp 29-35 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis psoriatic arthritis bimekizumab bispecific agent dualspecific agent Dermatology RL1-803
spellingShingle	psoriasis psoriatic arthritis bimekizumab bispecific agent dualspecific agent Dermatology RL1-803 Chiricozzi A De Simone C Fossati B Peris K Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
description	Andrea Chiricozzi,1,2 Clara De Simone,1,2 Barbara Fossati,2 Ketty Peris1,21Institute of Dermatology, Catholic University, Rome, Italy; 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyAbstract: Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.Keywords: psoriasis, psoriatic arthritis, bimekizumab, bispecific agent, dual specific agent
format	article
author	Chiricozzi A De Simone C Fossati B Peris K
author_facet	Chiricozzi A De Simone C Fossati B Peris K
author_sort	Chiricozzi A
title	Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_short	Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_full	Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_fullStr	Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_full_unstemmed	Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_sort	emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/b3f9927d63c04c45a0347abf4a3d2e87
work_keys_str_mv	AT chiricozzia emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential AT desimonec emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential AT fossatib emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential AT perisk emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential
_version_	1718400370505416704

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential

Ejemplares similares